Economic evaluation conducted from the perspective of the Spanish National Health System to assess the cost-effectiveness of maternal immunisation with the bivalent RSVpreF vaccine compared with no intervention for preventing respiratory syncytial virus (RSV) infection in infants.
Using a hypothetical cohort model and a Markov-type process, the study estimated clinical outcomes, costs and QALYs.
Results showed that maternal vaccination could reduce RSV-related hospitalisations, emergency department visits, primary care visits and deaths, while generating cost savings for the healthcare system.
Maternal immunisation was found to be a dominant strategy compared with no prevention.